Histogenics (NASDAQ:HSGX) Upgraded at ValuEngine

ValuEngine upgraded shares of Histogenics (NASDAQ:HSGX) from a hold rating to a buy rating in a research note released on Thursday, ValuEngine reports.

HSGX traded up $0.01 on Thursday, reaching $0.19. The company’s stock had a trading volume of 8,789,916 shares, compared to its average volume of 4,139,624. The business has a 50 day simple moving average of $0.20. The company has a market capitalization of $17.37 million, a P/E ratio of -0.24 and a beta of 3.27. Histogenics has a fifty-two week low of $0.08 and a fifty-two week high of $3.00.

Histogenics (NASDAQ:HSGX) last announced its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.05). As a group, equities analysts predict that Histogenics will post -0.03 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Histogenics stock. Geode Capital Management LLC acquired a new stake in Histogenics Corp (NASDAQ:HSGX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 291,743 shares of the biotechnology company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.47% of Histogenics at the end of the most recent quarter. Institutional investors and hedge funds own 11.44% of the company’s stock.

Histogenics Company Profile

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Featured Story: Why do companies pay special dividends?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.